1-9 of 9
Jane Shingles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib plus rituximab leads to superior progression-free and overall survival to FCR in previously untreated CLL: Results of the Phase III NCRI FLAIR trial

Free
Talha Munir, Sean Girvan, Annah Muli, David Cairns, David Allsup, Adrian Bloor, Abraham Mullasseril Varghese, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey Neilson, Nicholas Pemberton, Gamal Sidra, Nick Morley, Kate Cwynarski, Toby Eyre, Francesco Forconi, Simona Gatto, Shankara Paneesha, Christopher Fox, Dena Howard, Anna Hockaday, Julia Brown, Sharon Jackson, David Stones, Sue Bell, Natasha Greatorex, Nichola Webster, Jane Shingles, Surita Dalal, Piers Patten, Andy Rawstron, Peter Hillmen
Journal: Blood
Blood (2025) 146 (Supplement 1): 2128.
https://doi.org/10.1182/blood-2025-2128
Published: 2025
Journal Articles

MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial

Free
Surita Dalal, Jane Shingles, Sean Girvan, David Cairns, Paul Glover, Helen Warren, Thomas Grand, Nichola Webster, Andy Rawstron, Darren Newton, Charlotte Evans, Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, Natasha Greatorex, David Stones, David Allsup, Adrian Bloor, Anita Sarma, Abraham Mullasseril Varghese, Peter Hillmen, Talha Munir
Journal: Blood
Blood (2025) 146 (Supplement 1): 679.
https://doi.org/10.1182/blood-2025-679
Published: 2025
Journal Articles

Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.

Free
Andy Rawstron, David Cairns, Nichola Webster, Surita Dalal, Jane Shingles, Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, Natasha Greatorex, David Stones, David Allsup, Adrian Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2025) 146 (Supplement 1): 794.
https://doi.org/10.1182/blood-2025-794
Published: 2025
Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Free
Surita Dalal, Anita Sarma, Jane Shingles, Paul Glover, Helen Warren, Thomas Grand, Nichola Webster, Andy Rawstron, Darren Newton, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4637.
https://doi.org/10.1182/blood-2023-180527
Published: 2023
Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Free
Anita Sarma, Charlotte Evans, Surita Dalal, Nichola Webster, Andy Rawstron, Jane Shingles, Darren Newton, David Allan Cairns, Paul Glover, Thomas Grand, Helen Warren, Sue Bell, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4636.
https://doi.org/10.1182/blood-2023-188597
Published: 2023
Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Free
Talha Munir, Alexandra Pitchford, Adrian Bloor, Andrew Pettitt, Piers E.M. Patten, Francesco Forconi, Anna Schuh, Christopher P Fox, Simona Gatto, Ben Kennedy, John Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Nichola McWhirter, Jane Shingles, Kate Cwynarski, Shankara Paneesha, David Allsup, Andrew Rawstron, Peter Hillmen
Journal: Blood
Blood (2022) 140 (Supplement 1): 231–233.
https://doi.org/10.1182/blood-2022-170463
Published: 2022
Journal Articles

Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia

Free
Ruth M de Tute, MSc, Jane Shingles, PhD, Andy C. Rawstron, PhD, Roger G Owen, MD
Journal: Blood
Blood (2014) 124 (21): 3425.
https://doi.org/10.1182/blood.V124.21.3425.3425
Published: 2014
Journal Articles

Insights Into The Natural History Of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis Of The Presenting Clinical, Haematological and Flow Cytometric Features Of 705 Patients Leads To Improved Classification and Prediction Of Clinical Course

Free
Stephen John Richards, PhD, Richard Kelly, MD, Anita Hill, MBChB, PhD, Anita Dickinson, MSc, Fiona Cullen, MSc, Jane Shingles, PhD, Matthew Cullen, MSc, Peter Hillmen, MB ChB, PhD
Journal: Blood
Blood (2013) 122 (21): 3718.
https://doi.org/10.1182/blood.V122.21.3718.3718
Published: 2013
Journal Articles

Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.

Free
Andy C Rawstron, BSc, PhD, Darren J Newton, Ruth M. de Tute, Jane Shingles, Fiona L Bennett, Paul A.S. Evans, Sheila J.M. O’Connor, Andrew S Jack, Peter Hillmen
Journal: Blood
Blood (2008) 112 (11): 2076.
https://doi.org/10.1182/blood.V112.11.2076.2076
Published: 2008